公开(公告)号：US20230201624A1

公开(公告)日：2023-06-29

申请号：US17850425

申请日：2022-06-27

申请人： Immunolight, LLC ,  Duke University

发明人： Tuan VO-DINH ,  Jonathan P. SCAFFIDI ,  Venkata Gopal Reddy CHADA ,  Benoit LAULY ,  Yan ZHANG ,  Molly K. GREGAS ,  Ian Nicholas STANTON ,  Joshua T. STECHER ,  Michael J. THERIEN ,  Frederic A. BOURKE, JR. ,  Harold WALDER ,  Zak FATHI ,  Jennifer A. AYRES ,  Zhenyuan ZHANG ,  Joseph H. SIMMONS ,  Stephen John NORTON

IPC分类号： A61N5/06 ,  A61K49/00 ,  A61N1/40 ,  A61N5/02 ,  A61B5/00 ,  A61B5/055 ,  A61B6/00 ,  A61K41/00 ,  A61M5/00 ,  A61L2/00

CPC分类号： A61N5/062 ,  A61K49/0039 ,  A61N1/406 ,  A61N5/02 ,  A61N5/0601 ,  A61B5/0059 ,  A61B5/0071 ,  A61B5/055 ,  A61B5/4848 ,  A61B6/481 ,  A61K41/0052 ,  A61M5/007 ,  A61K41/0042 ,  A61K41/0061 ,  A61L2/0047 ,  A61L2/08

摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

公开(公告)号：US20220062419A1

公开(公告)日：2022-03-03

申请号：US17227753

申请日：2021-04-12

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Mark OLDHAM ,  Justus ADAMSON ,  Mark W. DEWHIRST ,  Paul YOON ,  Harold WALDER ,  Frederic A. Bourke, JR. ,  Zakaryae FATHI ,  Wayne F. BEYER, JR.

IPC分类号： A61K41/00 ,  A61N5/06 ,  A61K31/655 ,  A61K33/02 ,  A61K31/409 ,  A61K31/525 ,  A61K31/352 ,  A61K31/403 ,  A61K33/242 ,  A61K33/244 ,  A61K33/24 ,  A61N5/10

摘要： A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.

公开(公告)号：US20160325111A1

公开(公告)日：2016-11-10

申请号：US15151642

申请日：2016-05-11

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Frederic A. BOURKE, JR. ,  Tuan VO-DINH ,  Harold WALDER

IPC分类号： A61N5/06 ,  A61N5/02 ,  A61N5/10 ,  A61K41/00 ,  A61K47/48

CPC分类号： A61N5/062 ,  A61K41/0057 ,  A61K41/0061 ,  A61K47/6923 ,  A61N5/022 ,  A61N5/0618 ,  A61N5/0622 ,  A61N5/10 ,  A61N2005/0642 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1098

摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

摘要翻译： 用于修饰介导或与生物活性相关的靶结构的产物，组合物，系统和方法，包括治疗由病毒，细胞，亚细胞结构介导或与靶结构相关的疾病，病症或疾病 或胞外结构。 所述方法可以通过向受试者施加起始能量以非侵入性方式原位进行，从而直接或经由调节剂产生对靶结构的作用或改变。 所述方法还可以通过向受试者原位施加引发能量来直接或经由能量调节剂活化药剂，任选地在存在一种或多种等离子体激元活性剂的情况下进行，从而产生效果或改变 目标结构。 包含配制或配置的产品或组合的套件以及用于实施这些方法的系统。

公开(公告)号：US20240042233A1

公开(公告)日：2024-02-08

申请号：US18360187

申请日：2023-07-27

申请人： Immunolight, LLC ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE, JR. ,  Zakaryae FATHI ,  Wayne F. BEYER, JR. ,  Mark DEWHIRST ,  Mark OLDHAM ,  Justus ADAMSON ,  Michael NOLAN

IPC分类号： A61N5/06 ,  A61K41/17 ,  A61K39/00 ,  A61K41/00 ,  A61K49/04 ,  A61N5/02 ,  A61N5/10

CPC分类号： A61N5/062 ,  A61K41/17 ,  A61K39/0011 ,  A61K41/0066 ,  A61K49/0423 ,  A61N5/022 ,  A61N5/10 ,  A61N5/1081 ,  A61K2039/585 ,  A61N2005/0627 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1089 ,  A61N2005/1098

摘要： A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

公开(公告)号：US20180344850A1

公开(公告)日：2018-12-06

申请号：US15992852

申请日：2018-05-30

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Frederic A. BOURKE, JR. ,  Mark DEWHIRST ,  Neil SPECTOR ,  Paul YOON ,  Justus ADAMSON ,  David ALCORTA ,  Kim LYERLY ,  Leihua LIU ,  Takuya OSADA ,  Mark OLDHAM ,  Zakaryae FATHI ,  Wayne F. BEYER ,  Harold WALDER

IPC分类号： A61K41/00 ,  A61K31/37 ,  A61K45/06 ,  A61K9/00

摘要： A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.

公开(公告)号：US20170162537A1

公开(公告)日：2017-06-08

申请号：US15382835

申请日：2016-12-19

申请人： Immunolight, LLC ,  Duke University

发明人： Zakaryae FATHI ,  James CLAYTON ,  Harold WALDER ,  Frederic A. BOURKE, JR.

IPC分类号： H01L23/00 ,  B32B37/12 ,  B32B37/18 ,  C09K11/77 ,  H01L25/00 ,  C09J133/08 ,  C09K11/02 ,  B32B38/00 ,  H01L25/065

CPC分类号： H01L24/83 ,  A61B17/0057 ,  A61L24/06 ,  B32B3/266 ,  B32B7/14 ,  B32B9/04 ,  B32B37/1284 ,  B32B37/18 ,  B32B38/0008 ,  B32B2037/1253 ,  B32B2457/00 ,  B32B2457/08 ,  B32B2457/14 ,  B41J2/17559 ,  C08K3/00 ,  C09J4/00 ,  C09J9/02 ,  C09J11/04 ,  C09J11/06 ,  C09J133/08 ,  C09K11/02 ,  C09K11/7769 ,  C09K11/777 ,  H01L23/5226 ,  H01L24/32 ,  H01L25/0657 ,  H01L25/50 ,  H01L2224/16225 ,  H01L2224/32225 ,  H01L2224/48091 ,  H01L2224/48227 ,  H01L2224/73204 ,  H01L2224/73253 ,  H01L2224/73265 ,  H01L2224/83192 ,  H01L2224/83855 ,  H01L2224/92125 ,  H01L2225/06524 ,  H01L2225/06589 ,  H01L2924/07811 ,  H01L2924/1461 ,  H01L2924/15311 ,  Y10T428/2852 ,  H01L2924/00014 ,  H01L2924/00

摘要： A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.

公开(公告)号：US20160263393A1

公开(公告)日：2016-09-15

申请号：US15045524

申请日：2016-02-17

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Tuan VO-DINH ,  Jonathan P. SCAFFIDI ,  Venkata Gopal Reddy CHADA ,  Benoit LAULY ,  Yan ZHANG ,  Molly K. GREGAS ,  Ian Nicholas STANTON ,  Joshua T. STECHER ,  Michael J. THERIEN ,  Frederic A. BOURKE, JR. ,  Harold WALDER ,  Zak FATHI ,  Jennifer A. AYRES ,  Zhenyuan ZHANG ,  Joseph H. SIMMONS ,  Stephen John NORTON

IPC分类号： A61N5/06 ,  A61N1/40 ,  A61N5/10 ,  A61K41/00 ,  A61M5/00 ,  A61B6/00 ,  A61B5/055 ,  A61N5/02 ,  A61B5/00

CPC分类号： A61N5/062 ,  A61B5/0059 ,  A61B5/0071 ,  A61B5/055 ,  A61B5/4848 ,  A61B6/481 ,  A61K41/0042 ,  A61K41/0052 ,  A61K41/0061 ,  A61K49/0039 ,  A61L2/0047 ,  A61L2/08 ,  A61L2202/21 ,  A61L2202/22 ,  A61M5/007 ,  A61N1/406 ,  A61N5/02 ,  A61N5/0601 ,  A61N5/0618 ,  A61N5/0622 ,  A61N5/0624 ,  A61N5/10 ,  A61N2005/063 ,  A61N2005/0656 ,  A61N2005/0659 ,  A61N2005/0662 ,  A61N2005/067 ,  A61N2005/1098

摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

摘要翻译： 用于修饰介导或与生物活性相关的靶结构的产物，组合物，系统和方法，包括治疗由病毒，细胞，亚细胞结构介导或与靶结构相关的疾病，病症或疾病 或胞外结构。 所述方法可以以非侵入性方式在原位进行，通过将具有金属壳的纳米颗粒放置在受试者的靶结构附近的表面的至少一部分上，并向受试者施加引发能量，从而产生 直接或通过调制剂对目标结构的影响或改变。 纳米颗粒在暴露于第一波长λ1时被配置为产生具有比第一波长λ1更高的能量的辐射的第二波长λ2。 所述方法还可以通过向受试者原位施加引发能量来直接或经由能量调节剂活化药剂，任选地在一种或多种等离子体激活剂活性剂的存在下进行，从而产生对其的作用或改变 目标结构。 包含配制或配置的产品或组合的套件以及用于实施这些方法的系统。

公开(公告)号：US20230029054A1

公开(公告)日：2023-01-26

申请号：US17931105

申请日：2022-09-09

申请人： Immunolight, LLC ,  Duke University

发明人： Frederic A. BOURKE, JR. ,  Tuan VO-DINH ,  Harold WALDER

IPC分类号： A61N5/06 ,  A61K41/00 ,  A61K47/69 ,  A61N5/02 ,  A61N5/10

摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

公开(公告)号：US20220080045A1

公开(公告)日：2022-03-17

申请号：US17538770

申请日：2021-11-30

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE, JR. ,  Zakaryae FATHI ,  Wayne F. BEYER ,  Mark OLDHAM ,  Justus ADAMSON ,  Michael NOLAN

IPC分类号： A61K41/00 ,  A61K31/37 ,  A61N5/06 ,  A61N5/10

摘要： A method for treating a disease in a subject in need thereof is provided involving infusing 8-methoxypsoralen (8-MOP) and a phosphor-containing drug activator into a diseased site in the subject; and delivering a dose of x-rays to the subject for production of the ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose including a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor, wherein the phosphor-containing drug activator includes an admixture of two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays; the two or more phosphors including Zn2SiO4:Mn2+ and (3Ca3(PO4)2Ca(F, Cl)2: Sb3+, Mn2+) at a ratio (Zn2SiO4:Mn2+):(3Ca3(PO4)2Ca(F, Cl)2: Sb3+, Mn2+)) of from 1:10 to 10:1; wherein each of the two or more phosphors have at least one coating selected from an ethyl cellulose coating or a diamond-like carbon coating.

公开(公告)号：US20200368547A1

公开(公告)日：2020-11-26

申请号：US16860623

申请日：2020-04-28

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Frederic A. BOURKE, JR. ,  Harold WALDER ,  Zakaryae FATHI ,  Michael J. THERIEN ,  Mark W. DEWHIRST ,  Ian N. STANTON ,  Jennifer Ann AYRES ,  Diane Renee FELS ,  Joseph A. HERBERT

IPC分类号： A61N5/06 ,  A61K41/00 ,  A61N5/10

摘要： A method for treating a disease, disorder, or condition in a subject in need thereof, by administering either or both of (i) at least one photoactivatable pharmaceutical agent, or (ii) a first plurality of energy-emitting particles, into the subject in a region of the disease, disorder, or condition, whereby the administering is performed through inhalation; and applying an applied electromagnetic energy to the subject, wherein the applied electromagnetic energy directly or indirectly activates the at least one photoactivatable pharmaceutical agent, when present, and wherein when the first plurality of energy-emitting particles is present, the first plurality of energy-emitting particles absorbs the applied energy and emits an emitted electromagnetic energy, wherein the emitted electromagnetic energy interacts directly with the region of the disease, disorder, or condition or activates the at least one photoactivatable pharmaceutical agent.